Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04404283 · ClinicalTrials.gov registry record · Phase 3
Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL
A Phase 3 study of Diffuse Large B Cell Lymphoma, sponsored by Seagen, a wholly owned subsidiary of Pfizer.
- Active
- Registry status
- Phase 3
- Development phase
- 238
- Enrollment target
- 20
- Study locations
NCT04404283 is a Phase 3 study of Diffuse Large B Cell Lymphoma that is active but no longer recruiting, run by Seagen, a wholly owned subsidiary of Pfizer. The registered enrollment target is 238 participants, above the 217-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (10% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT04404283, a Phase 3 study of Diffuse Large B Cell Lymphoma, is active but no longer recruiting, sponsored by Seagen, a wholly owned subsidiary of Pfizer.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 238 participants
- Enrollment target
- 20
- Study locations
Study Summary
Participants in this study will have diffuse large B-cell lymphoma (DLBCL) that has come back or not gotten better with treatment. The trial will study whether brentuximab vedotin plus two drugs works better to treat this type of cancer than the two drugs alone. Participants will be randomly assigned to get either brentuximab vedotin or placebo. The placebo will look like brentuximab vedotin, but has no medicine in it. Since the study is "blinded," participants and their doctors will not know whether a participant gets brentuximab vedotin or placebo. All participants in the study will get rituximab and lenalidomide. These are drugs that can be used to treat DLBCL.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Rituximab
- DRUG Lenalidomide
- DRUG Brentuximab vedotin
Study Locations (20)
Florida
- Florida Cancer Specialists - Bonita Springs
- Florida Cancer Specialists - Bradenton
- Florida Cancer Specialists - Cape Coral
- Florida Cancer Specialists - Daytona Beach
- Florida Cancer Specialists - Fort Myers
- Florida Cancer Specialists - Fort Myers
- Florida Cancer Specialists - Naples
- Florida Cancer Specialists - Port Charlotte
- Florida Cancer Specialists - Sarasota
- Florida Cancer Specialists - Sarasota
- Florida Cancer Specialists - Stuart
- Florida Cancer Specialists - Venice
- Florida Cancer Specialists - Venice
- Florida Cancer Specialists - Vero Beach
- Florida Cancer Specialists - Wellington
- Florida Cancer Specialists - West Palm Beach
California
- University of California Davis Comprehensive Cancer Center - Sacramento
- University of California Davis Medical Center - Sacramento
Alabama
- Central Alabama Research - Birmingham
Kansas
- MidAmerica Division, Inc. c/o Menorah Medical Center - Overland Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 238 participants |
| Start Date | 2020-08-20 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04404283
The ClinicalTrials.gov registry entry for NCT04404283 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 238 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 217-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (10% higher). The listed sponsor is Seagen, a wholly owned subsidiary of Pfizer, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diffuse Large B Cell Lymphoma appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT04404283 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Florida, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT04404283 about?
NCT04404283 is a clinical study titled "Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL". Participants in this study will have diffuse large B-cell lymphoma (DLBCL) that has come back or not gotten better with treatment. The trial will study whether brentuximab vedotin plus two drugs works better to treat this type of cancer than the two drugs alone. Participants will be randomly assign...
What is the current status of trial NCT04404283?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 238 participants. The study started on 2020-08-20. Estimated completion is 2026-12-31.
What conditions does trial NCT04404283 study?
This clinical trial studies the following conditions: Diffuse Large B Cell Lymphoma.
What interventions are being tested in trial NCT04404283?
The interventions under investigation include: Placebo (OTHER), Rituximab (DRUG), Lenalidomide (DRUG), Brentuximab vedotin (DRUG).
Who is sponsoring clinical trial NCT04404283?
This trial is sponsored by Seagen, a wholly owned subsidiary of Pfizer, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04404283 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diffuse Large B Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Long-term Extension Study of PCI-32765 (Ibrutinib)
RECRUITING · Phase 3
-
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
RECRUITING · Phase 3
-
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
RECRUITING · Phase 3
-
Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
ACTIVE NOT RECRUITING · Phase 3
-
A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
ACTIVE NOT RECRUITING · Phase 3
-
A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.